

## References

### Continuing Education #98-004: Nonherbal Dietary Supplements

—Prepared for subscribers of *Pharmacist's Letter* and *Prescriber's Letter*—

#### Chromium

1. Mertz, W. et al. Relation of glucose tolerance factor to impaired intravenous glucose tolerance of rats on stock diets. *Am J Physiol* 196:614-18, 1959.
2. Jeejeebhoy, KN et al. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition. *Am J Clin Nutr* 30:531-538, 1977.
3. Freund, H. et al. Chromium deficiency during total parenteral Nn. *JAMA* 241:496-498, 1979.
4. Anderson, R.A. Essentiality of chromium in humans. *Sci Total Environ* 86:75-81, 1989.
5. Anderson, R.A. Chromium and parenteral nutrition. *Nutrition* 11:83-86, 1995.
6. Rabinowitz, M.B. et al. Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. *Diabetes Care* 6:319-27, 1983.
7. Uusitupa, M.I. et al. Chromium supplementation in impaired glucose tolerance of elderly: effects of blood glucose, plasma insulin, C-peptide and lipid levels. *Br J Nutr* 68:209-16, 1992.
8. Sherman, L. et al. Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus. *Metabolism* 17:439-42, 1968.
9. Ravina, A. et al. Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. *J Trace Elem Exp Med* 8:183-190, 1995.
10. Anderson, R.A. et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with Type 2 diabetes. *Diabetes* 46:1786-91, 1997.
11. Fox, G.N. et al. Chromium picolinate supplementation for diabetes mellitus. *J Fam Pract* 46:83-85, 1998.
12. Jovanovic-Peterson, I. et al. Vitamin and mineral deficiencies which may predispose to glucose intolerance of pregnancy. *J Am Coll Nutr* 15:14-20, 1996.
13. Anderson, R.A. et al. Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia. *Metabolism* 36:351-355, 1987.
14. Abraham, A.S. et al. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. *Metabolism* 41:768-771, 1992.
15. Trent L.K. et al. Effects of chromium picolinate on body composition. *J Sports Med Phys Fitness*, 35:273-80, 1995.
16. Bahadori, B. et al. Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet. *Acta Med Austriaca* 24:185-7 1997.
17. Grant, K.E. Chromium and exercise training: effect on obese women. *Med Sci Sports Exerc* 29:992-8, 1997.
18. Anderson, R.A. et al. Dietary chromium effects on tissue chromium concentrations and chromium absorption in rats. *J Trace Elem Exp Med* 9:11-25, 1996.
19. Mertz, W. et al. Present knowledge of the role of chromium. *Fed Proc* 33:2275-80, 1974.
20. Davis, C.M. Chromium oligopeptide activates insulin receptor tyrosine kinase. *Biochemistry* 36:4382-5, 1997.
21. Porter, J.F. et al. Glucose Metabolism in glucose-intolerant older people during chromium supplementation. *Metabolism* 34:199-204, 1985.
22. Reading, S.A. Chromium picolinate. *J Fla Med Assoc* 83(1):29-31 1996.
23. Cerulli, J. et al. Chromium picolinate toxicity. *Ann Pharmacother* 32:428-31, 1998.
24. Stearns, D.M. et al. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. *FASEB J* 9:1643-8, 1995.
25. Stearns, D.M. et al. Chromium (III) picolinate [letter, author reply] *FASEB J* 10: 367-9, 1996.
26. Roeback, J.R. Jr. et al. Effects of chromium supplementation on serum high-density lipoprotein cholesterol in men taking beta-blockers. *Ann Inter Med* 115:917-24, 1991.

More . . .

27. Mossop, R.T. Diabetogenic effect of thiazides and the relation to chromium: a preliminary report. *Cent Afr J Med* 7:129-31, 1985.
28. Cefalu W., Bell-Farrow A, Wang Z, McBride D, Stegner J, Terry J, Morgan T. The effect of chromium supplementation on carbohydrate metabolism and body fat distribution (abstr). *Diabetes* 1997;46(Suppl 1):55A.
29. Hasten D.L., et al. Effects of chromium picolinate on beginning weight training students. *Int. J Sports Nutr* 1992;2:343.
30. Hallmark, M.A., et al. Effects of chromium and resistive training on muscle strength and body composition. *Med Sci Sports Exerc* 1996;28:139.
31. Almada A., et al. Effects of ingesting a nutritional supplement containing chromium picolinate and boron on body composition during resistance training. *FASEB J* 1995;9:A1015.
32. Clancy S., et al. Effects of chromium picolinate supplementation on body composition, strength and urinary chromium loss in football players. *Int J Sports Nutr* 1994;4:142.
33. Trent, L.K., Thieding-Cancel D. Effects of chromium picolinate on body composition in a remedial conditioning program. *NHRC Publication* 1995;94-20.
34. Wasser W.G., Feldman NS, D'Agati VD. Chronic renal failure after ingestion of over-the-counter chromium picolinate, *Ann Intern Med* 1997 Mar 1;126(5):410.
35. Martin W.R., Fuller RE. Suspected chromium picolinate-induced rhabdomyolysis. *Pharmacotherapy* 1998 Jul-Aug;18(4):860.

### **Co-Enzyme Q-10**

1. Greenberg S., Frishman W.H. Co-enzyme Q10: a new drug for cardiovascular disease. *J Clin Pharmacol* 1990;30:596-608.
2. Baggio E., Gandini R., Plancer A.C., et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. *Molec Aspects Med* 1994;15 (Suppl):S287-94.
3. Langsjoen P.H., Langsjoen, P., Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. *Am J Cardiol* 1990;65:521-3.
4. Folkers K., Langsjoen P., Langsjoen P.H. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. *Biochem Biophys Res Commun* 1992;182:247-53.
5. Digiesi B., Cantini F., Oradei A., et al. Coenzyme Q10 in essential hypertension. *Molec Aspects Med* 1994;15 (Suppl):S257-63.
6. Hanioka T., Tanaka M., Ojima M., Shizukuishi S., Folkers K. Effect of topical application of coenzyme Q10 on adult periodontitis. *Molec Aspects Med* 1994;15 (Suppl):S241-8.
7. Watts T.L.P. Coenzyme Q10 and periodontal treatment: is there any beneficial effect? *Br Dent J* 1995;178:209-13.
8. Folkers K., Morita M., McRee J. The activities of coenzyme Q10 and vitamin B6 for immune responses. *Biochem Biophys Res Commun* 1993;193:88-92.
9. Segal-Isaacson A.E., Rand C.J. Antioxidant supplementation in HIV/AIDS. *Nurs Pract* 1995;20:8,11-14.
10. Folkers K., Hanioka T., Xia L.J., McRee J.T., Langsjoen P. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS-related complex. *Biochem Biophys Res Commun* 1991;176:786-91.
11. Ubiquinone. In: Olin B.R., ed. *The Lawrence review of natural products*. St. Louis, MO: *Facts and Comparisons*; 1997.
12. Lockwood K., Moesgaard S., Hanioka R., Folkers K. Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. *Molec Aspects Med* 1994;15 (Suppl):S231-40.
13. Suzuki S., Hinokio Y., Ohtomo M., et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. *Diabetologia* 1998;41:584-8.
14. Lonnot K., Metsa-Ketela R., Alho H. The role of coenzyme Q-10 in aging: A follow-up study on life-long oral supplementation Q-10 in rats. *Gerontology* 1995;41 (Suppl 2):109-20.

More . . .

15. Malm C., Svensson M., Ekblom B., Sjodin B. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. *Acta Physiol Scand* 1997;161:379-84.
16. Weston S.B., Zhou S., Weatherby R.P., Robson S.J. Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes? *Int J Sport Nutr* 1997;7:197-206.
17. Ernster L., Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. *Biochem Biophys Acta* 1995;1271:195-204.
18. Kontush A., Reich A., Baum K., et al. Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia. *Atherosclerosis* 1997;129:119-26.
19. Kishi T., Kishi H. T, Folkers K. Bioenergetics in clinical medicine. XI. Studies on coenzyme Q and diabetes mellitus. *J Med* 1976;7:307-21.
20. Ghirlanda G., Oradei A., Manto A. et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study. *J Clin Pharmacol* 1993;33:226-9.
21. Spigset O. Reduced effect of warfarin caused by ubidecarenone. *Lancet* 1994;334:1372-3.
22. CoQ-10. Acton, M.A.: Mother Nature's General Store, Inc. Available online at <http://www.mothenature.com/coq10.htm>; 1998.
23. Koroshetz W.J., Jenkins B.G., Beal M.F. Energy Metabolism defects in Huntington's disease and effects of coenzyme Q10. *Ann Neurol* 1997 Feb;41(2):160-65.
24. Feigin A., Kiebertz K., Como P., et al. Assessment of coenzyme Q tolerability in Huntington's disease. *Mov Disord* 1996 May;11(3):321-3.
25. Beal M.F. Neurochemistry and toxin models in Huntington's disease. *Curr Opin Neurol* 1994 Dec;7(6):542.
26. Hanaki Y., et al. Coenzyme Q10 and coronary artery disease. *Clin Investig* 1993;71 (8 suppl):S112-5.

### ***Creatine***

1. Maughan R.J. Creatine supplementation and exercise performance. *Int J Sport Nutr* 5:94-101, 1995.
2. Brannon T.A. et al. Effects of creatine loading and training on running performance and biochemical properties of rat skeletal muscle. *Med Sci Sports Exerc* 29:489-95, 1997.
3. Rossiter H.B. et al. The effect of oral creatine supplementation on the 1000-m performance of competitive rowers. *J Sports Sci* 14:175-9, 1996.
4. Peyrebrune M.C. et al. The effects of oral creatine supplementation on performance in single and repeated sprint. *J Sports Sci* 16:271-9, 1998.
5. Volek J.S. et al. Creatine supplementation enhances muscular performance during high-intensity resistance exercise. *J Am Diet Assoc* 97:765-70, 1997.
6. Prevost M.C. et al. Creatine supplementation enhances intermittent work performance. *Res Q Exerc Sport* 68:233-40, 1997.
7. Thompson C.H. et al. Effect of creatine on aerobic and anaerobic metabolism in skeletal muscle in swimmers. *Br J Sports Med* 30:222-5, 1996.
8. Mujika I., et al. Creatine supplementation does not improve sprint performance in competitive swimmers. *Med Sci Sports Exerc* 28:1435-41, 1996.
9. Hultman E. Muscle creatine loading in men. *J Appl Physiol* 81:232-7, 1996.
10. Maughan R.J. Creatine supplementation and exercise performance. *Int J Sport Nutr* 5:94-101, 1995.
11. Mujika I. and Padilla S. Creatine supplementation as an ergogenic acid for sports performance in highly trained athletes: a critical review. *Int J Sports Med*, 18:491-6, 1997.
12. Modica P. Creatine supplements could help improve weight lifting performance, but not endurance. *Medical Tribune: Internist & Cardiologist Edition* 38(16): 1997.

*More. . .*

**DHEA**

1. Nestler J.E., Clore J.N., Blackard W.G. Metabolism and actions of dehydroepiandrosterone in humans. *J Steroid Biochem Molec Biol* 1991;40:599-605.
2. Baulieu E. Dehydroepiandrosterone (DHEA): A fountain of youth? *J Clin Endocrinol Metab* 1996;81:3147-51.
3. Wolf O.T., Neumann O., Hellhammer D.H., et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. *J Clin Endocrinol Metab* 1997;82:2363-67.
4. Morales A.J., Nolan J.J., Nelson J.C., Yen S.S.C. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. *J Clin Endocrinol Metab* 1997;78:1360-67.
5. DHEA — the promise of youth and health. *University of California at Berkeley Wellness Letter* 1996 Jan;12:1-2.
6. Yen S,S,C,, Morales A,J,, Khorram O. Replacement of DHEA in aging men and women. *Ann NY Acad Sci* 1995;774:128-42.
7. Di Monaco M., Pizzini A., Gatto V., et al. Role of glucose-6-phosphate dehydrogenase inhibition in the antiproliferative effects of dehydroepiandrosterone on human breast cancer cells. *Br J Cancer* 1997;75:589-92.
8. Casson P.R., Andersen R.N., Herrod H.G., et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. *Am J Obstet Gynecol* 1993;169:1536-9.
9. Miller R.A. DHEA - Brass ring or red herring? *JAGS* 1997;45:1402-3.
10. Araneo B., Dowell T., Woods M.L., Daynes R., Judd M. Evans T. DHEAS as an effective vaccine adjuvant in elderly humans. *Ann NY Acad Sci* 1995;774:232-48.
11. Danenberg H.D., Ben-Yehuda A., Zakay-Rones Z. Gross D.J. Friedman G. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects. *J Clin Endocrinol Metab* 1997;82:2911-4.
12. Degelau J., Guay D., Hallgren H. The effect of DHEAS on influenza vaccination in aging adults. *JAGS* 1997;45:747-51.
13. Centurelli M.A., Abate M.A. The role of dehydroepiandrosterone in AIDS. *Ann Pharmacother* 1997;31:639-42.
14. Jacobson M.A., Fusaro R.E. Galmarini M., Lang W. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499. *J Infect Dis* 1991;164:864-8.
15. Mulder J.W., Jos Frisson P.H. Krijnen P., et al. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. *J Infect Dis* 1992;165:413-8.
16. Wisniewski T.L., Hilton C.W., Morse E.V., Svec F. The relationship of serum DHEA-S and cortisol levels to measures of immune function in human immunodeficiency virus-related illness. *Am J Med Sci* 1993;305:79-83.
17. Christeff N., Gherbi N., Mammes O., et al. Serum cortisol and DHEA concentrations during HIV infection. *Psychoneuroendocrinology* 1997;22 (Suppl 1):S11-S18.
18. Brind J. Spotlight on DHEA: A marker for progression of HIV infection? *J Lab Clin Med* 1996;127:522-3.
19. Dehydroepiandrosterone (DHEA). *Med Lett Drug Ther* 1996;38:91-2.
20. van Vollenhoven R.F., Engleman E.G., McGuire J.L. Dehydroepiandrosterone in systemic lupus erythematosus: Results of a double-blind, placebo-controlled, randomized clinical trial. *Arthr Rheum* 1995;38:1826-31.
21. van Vollenhoven R.F., Morabito L.M., Engleman E.G., McGuire J.L. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. *J Rheumatol* 1998;25:285-9.
22. National Institute on Aging. Pills, patches, and shots: Can hormones prevent aging? [fact sheet]. Bethesda, MD: *National Institutes of Health*; April 1997.
23. Schwartz A.G., Pashko L.L. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. *J Cell Biochem Suppl* 1995;22:210-17.
24. Hornsby P.J. DHEA: A biologist's perspective. *JAGS* 1997;45:1395-1401.

More. . .

25. Ebeling P., Koivisto V.A. Physiological importance of dehydroepiandrosterone. *Lancet* 1994;343:1479-81.
26. Labrie F., Belanger A., Simard J., Luu-The V., Labrie C. DHEA and peripheral androgen and estrogen formation: Intracrinology. *Ann NY Acad Sci* 1995;774:16-28.
27. McNeil C. Potential drug DHEA hits snags on way to clinic. *J Natl Cancer Inst* 1997;89:681-83.
28. Watson R.R., Huls A., Araghinikou M., Chung S. Dehydroepiandrosterone and diseases of aging. *Drugs Aging* 1996;9:274-91.
29. Scientific verdict still out on DHEA. *JAMA* 1996;276:1365-7.
30. Gronek D.M., Balbert E., Richert C., Zimmerman M. DHEA White Paper. Chatsworth, CA: Natrol Inc. Available online at <http://www.natrol.com/products/dhea.wp.html/>; 1996.
31. Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: A prospective, double-blind, randomized, placebo-controlled study. *Urology* 1999;53(3):590.

### **Glucosamine**

1. Crolle, G., D'Este, E. Glucosamine sulphate for the management of arthrosis; a controlled clinical investigation. *Curr.Med Res Opin* 7:104-109, 1980.
2. D'Ambrosio, E., et al, Glucosamine sulphate: a controlled clinical investigation in arthrosis. *Pharmatherapeutica*. 2:504-508, 1981.
3. Drovanti, A., et al. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-controlled double-blind investigation. *Clin Ther* 3:260-272, 1980.
4. Pujalte, J.M., et al. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthritis. *Curr Med Res Opin* 7:110-114, 1980.
5. Lopes Vaz, A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in out-patients. *Curr Med Res Opin* 8:145-149, 1982.
6. Rovati, L.C. Clinical research in osteoarthritis: design and results of short-term and long-term trials with disease-modifying drugs. *Int J Tissue React* 14:243-251, 1992.
7. Morreale, P. et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. *J Rheumatol* 23:1385-91, 1996.
8. Giordano N., et al. The efficacy and safety of glucosamine sulfate in the treatment of gonarthrosis. *Clin Ther* 147:99-105, 1996.
9. da Camara, C.C., Dowless, G.V. Glucosamine sulfate for osteoarthritis [see comments] *Ann Pharmacother* 32:580-7, 1998.
10. Barclay, T.S., et al. Glucosamine [see comments], *Ann Pharmacother* 32:574-9,1998.
11. McCarty, M.F. Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans. *Med Hypotheses* 48:245-51, 1997.
12. Kelly, G.S. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. *Altern Med Rev* 3:27-39, 1998.

### **Honey Bee Venom**

1. Diez Gomez M.L., Quirce Gancedo S., Julia de Paramo B. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy. *Allergologia et Immunopathologia* 1995;23(6):277-84.
2. Chang Y.H., Bliven M.L. Antiarthritic effect of bee venom. *Agents Actions* 1979;9:205-211.
3. Eiseman J.L., et al. Effect of honeybee (*Apis mellifera*) venom on the course of adjuvant-induced arthritis and depression of drug metabolism in the rat. *Biochem Pharmacol* 1982;31: 1139-46.
4. Hadjipetrou-Kourounakis L., Yiangou M. Bee venom and adjuvant-induced disease. *J Rheumatol* 1984;11:720.
5. Lorenzetti O.J., et al. Influence of bee venom in the adjuvant-induced arthritic rat model. *Res Commun Chem Pathol Pharmacol* 1972;4:339-352.
6. Wilkinson S. Is Bee Venom a Cure for Arthritis?
7. Kuthan F. Bee venom treatment of rheumatic disorders. Paper presented at the International Apicultural Congress of Apimondia, Bucharest, Romania. Original article in German. 1997.

More . . .

8. Kuthan F. Bee venom treatment of rheumatic disorders. Part 2. Paper presented at the International Apicultural Congress of Apimondia, Bucharest, Romania. Original article in German. 1997.
9. Bomalaski JS, et al. Rheumatoid arthritis synovial fluid phospholipase A2 activating protein (PLAP) stimulates human neutrophil degranulation and superoxide ion production. *Agents Actions* 1989;27:425.
10. Somerfield SD, et al. Bee venom melittin blocks neutrophil O<sub>2</sub>-production. *Inflammation* 1986;10:175.
11. Shkenderov S, Koburova K. Adolapin-a newly isolated analgetic and anti-inflammatory polypeptide from bee venom. *Toxicon* 1982;20:317.
12. Vick JA, Shipman WH. Effects of whole bee venom and its fractions (apamin and melittin) on plasma cortisol levels in the dog. *Toxicon* 10(4):377-80, 1972 Jun.
13. Scribilo D. Excerpts from *Am Bee J* 1996;136(2):107-109.  
<http://sunsite.unc.edu/pub/academic/agriculture/entomology/beekeeping/general/venom/therapy/bevenfaq.html>.
14. Steigerwaldt F et al. Standardized bee venom (SBV) therapy for arthritis. *Indust Med Surg* 1966;35:1045-1049.

### 5-HTP

1. Birdsall T.C. 5-Hydroxytryptophan: A Clinically-Effective Serotonin Precursor. *Altern Med Rev* 1998;3(4):271-280.
2. Hermes A.E. Drugdex Drug Evaluation: hydroxytryptophan. 3/98.
3. Coppen A., Whybrow P.C., Noguera R., et al. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. *Arch Gen Psychiatry* 1972;26(3):234-241.
4. Jensen K., Fruensgaard K., Ahlfors U.G., et al. Tryptophan/imipramine in depression. *Lancet* 1975;2(7941):920.
5. Rao B., Broadhurst A.D. Letter: Tryptophan and depression. *Br Med J* 1976;1(6007):460.
6. Glassman A.H., Platman S.R. Potentiation of a monoamine oxidase inhibitor by tryptophan. *J Psychiatr Res* 1969; 7(2):83-88.
7. Ayuso Gutierrez J.L., Alino J.J. Tryptophan and an MAOI (nialamide) in the treatment of depression. A double-blind study. *Int Pharmacopsychiatry* 1971; 6(2):92-97.
8. Coppen A., Shaw D.M., Herzberg B., Maggs R. Tryptophan in the treatment of depression. *Lancet* 1967;2(7527):1178-80
9. Alino J.J., Gutierrez J.L., Iglesias M.L. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study. *International Pharmacopsychiatry* 1976;11(1):8-15.
10. Nolan W.A., Van De Putte J.J, Dijken W.A., et al. L-5HTP in depression resistant to re-uptake inhibitors an open comparative study with tranlycypromine. *Br J Psychiatry* 1985;147:16-22.
11. Van Hiele L.J. L-5-hydroxytryptophan in depression: the first substitution therapy in psychiatry: the treatment of 99-out-patients with "therapy-resistant" depressions? *Neuropsychobiology* 1980;6:230-240.
12. Puttini P.S, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. *J Int Med Res* 1992;20(2):182-189.
13. Cangiano C., Ceci F., Cancino A., et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. *Am J Clin Nurt* 1992;56(5):863-67.
14. Abraham H.D. L-5-hydroxytryptophan for LSD-induced psychosis. *Am J Psychiatry* 1983;140:456-458.
15. Feit H., Kirkpatrick J., Van Woert M.H., et al. Myclonus, ataxia and hypoventilation: response to L-5-hydroxytryptophan. *Neurology* 1983;33:109-12.
16. Jimenez F.J., Roldan A., Zancada .F., et al. Spinal myoclonus: successful treatment with the combination of sodium valproate and L-5-hydroxytryptophan. *Clin Neuropharmac* 1991;14:186-90.
17. Kahn R.S., Westenberg H.G.M. L-5-hydroxytryptophan in the treatment of anxiety disorders. *J Affective Disorders* 1985;8:197-200.

More. . .

18. Trouillas P., Brudon F., Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan: a double-blind study with quantified data processing. *Arch Neurol* 1988;45:1217-1222.
19. Williams A., Goodenberger D. Caline D.B., et al. Palatal myclonus following herpes zoster ameliorated by 5-hydroxytryptophan and carbidopa. *Neurology* 1978;28:358-59.
20. Meyer JS, Welch KM, Dishmukh et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease. *J Amer Geriat Soc* 1977;25:289-98.
21. FDA Talk Paper. Impurities confirmed in dietary supplement 5-hydroxy-L-tryptophan. August 31, 1998.

### **Melatonin**

1. Chase J.E, Gidal B.E. Melatonin: therapeutic use in sleep disorders. *Ann Pharmacother* 1997;31:1218-1226.
2. Brzezinski A. Mechanisms of disease: melatonin in humans. *N Engl J Med* 1997;336(3):186-195.
3. Wagner J., Wagner M.L, Hening W.A. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. *Ann Pharmacother* 1998;32:680-691.
4. Penev P.D., Zee P.C. Melatonin: a clinical perspective. *Ann Neurol* 1997;42(4):545-553.
5. Johns Cupp M. Melatonin. *Am Fam Phys* 1997;56(5):1421-1425.
6. Okawa M., Uchiyama M., Ozaki S., et al. Melatonin treatment for circadian rhythm sleep disorders. *Jap Soc Sleep Res. Psyc & Clin Neurosci* Apr 1998;52(2):259-260.

### **Omega-3 Fatty Acids**

1. Appel L.J., Miller E.R., Seidler A.J., et al. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. *Arch Intern Med* 1993;153:1429-38.
2. Stone N.J. Fish consumption, fish oil, lipids, and coronary heart disease. *Circulation* 1996;94:2337-40.
3. Andreassen A.K., Hartmann A., Offstad J., et al. Hypertension prophylaxis with omega-3 fatty acids in heart transplant recipients. *J Am Coll Cardiol* 1997;29:1324-31.
4. Homan van der Heide J.J., Bilo H.J.G., Donker J.M., et al. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. *N Engl J Med* 1993;329:769-73.
5. Endres S., De Caterina R., Schmidt E.B., et al. n-3 polyunsaturated fatty acids: update 1995. *Eur J Clin Invest* 1995;25:629-38.
6. Daviglius M.L., Stamler J., Orenca A.J., et al. Fish consumption and the 30-year risk of fatal myocardial infarction. *N Engl J Med* 1997;336:1046-53.
7. Schmidt E.B., Dyerberg J. Omega-3 fatty acids. Current status in cardiovascular medicine. *Drugs* 1994;47:405-24.
8. Sacks F.M., Stone P.H., Gibson C.M., et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. *J Am Coll Cardiol* 1995;25:1492-8.
9. DeLuca P., Rothman D., Zurier R.B. Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. *Rheum Dis Clin North Am* 1995;21:759-77.
10. Lau C.S., Morley K.D., Belch J.J. Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis — a double-blind placebo controlled study. *Br J Rheumatol* 1993;32:982-9.
11. Kremer J.M. Clinical studies of omega-3 fatty acid supplementation in patients who have rheumatoid arthritis. *Rheum Dis Clin North Am* 1991;17:391-402.
12. Hawthorne A.B., Daneshmend T.K., Hawkey C.J., et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. *Gut* 1992;33:922-8.
13. Aslan A., Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. *Am J Gastroenterol* 1992;87:432-7.
14. Hodgson H.J. Keeping Crohn's disease quiet. *N Engl J Med* 1996;334:1599-1600.

More . . .

15. Belluzzi A., Brignole C., Campieri M., et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *N Engl J Med* 1996;334:1557-60.
16. Caygill C.P., Charlett A., Hill M.J. Fat, fish, fish oil and cancer. *Br J Cancer* 1996;74:159-64.
17. Harel Z., Biro F.M, Kottenhahn R.K, et al. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. *Am J Obstet Gynecol* 1996;174:1335-8.
18. Donadio J.V.J., Bergstralh E.J., Offord K.P., et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. *N Engl J Med* 1994;331:1194-9.
19. van Ypersele de Strihou C. Fish oil for IgA nephropathy? *N Engl J Med* 1994;331:1227-9.
20. Puri B.K., Richardson A.J. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. *Arch Gen Psych* 1998;55:188-9.
21. Knapp H.R. Omega-3 fatty acids in respiratory diseases: a review. *J Am Coll Nutr* 1995;14:18-23.
22. Soyland E., Funk J., Rajka G., et al. Effect of dietary supplementation with very long-chain n-3 fatty acids in patients with psoriasis. *N Engl J Med* 1993;328:1812-6.
23. McCarthy G.M., Kenny D. Dietary fish oil and rheumatic diseases. *Semin Arthritis Rheum* 1992;21:368-75.
24. Cairns J.A., Gill J., Morton B, et al. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. *Circulation* 1996;94:1553-60.
25. Ross E. The role of marine fish oils in the treatment of ulcerative colitis. *Nutr Rev* 1993;51:47-9.
26. De Caterina R., Endres S., Kristensen S.D., et al. n-3 fatty acids and renal diseases. *Am J Kidney Dis* 1994;24:397-415.
27. Kang J.X., Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies. *Circulation* 1996;94:1774-80.
28. Threlkeld D.S., Scott J.A., Bell W.L., et al. Drug Facts and Comparisons. St. Louis, MO: *Facts and Comparisons*; 1998.
29. Bucci K.K. Fish oil supplements. *Am Pharm* 1992;NS32:48-50.
30. Panush R.S., for the American College of Rheumatology Board of Directors. Position statement: Diet and arthritis. Atlanta, GA: American College of Rheumatology. Available online at <http://www.rheumatology.org/position/dietrev.html>; January 1996.

## **Selenium**

1. Salonen J.T., Salonen R., Lappetlainen R., et al. Risk of cancer in relation to serum concentrations of selenium and prospective data. *Br Med J* 1985;290:417-20.
2. Combs F.G. Jr, Combs S.B., ed. Selenium and cancer. In: The Role of Selenium in Nutrition, 1986, New York: *Acad Press*, 401-440.
3. Bastist G. Selenium. Preclinical studies of anticancer therapeutic potential. *Biol Trace Element Res* 1988;15:223-9.
4. Jackson M.L. Selenium: geochemical distribution and associations with human heart and cancer death rates and longevity in China and the United States. *Biol Trace Element Res* 1988;15:13-21.
5. Coates R.J., Weiss N.S., Daling J.R., et al. Serum levels of selenium and retinol and the subsequent risk of cancer. *Am J Epidem* 1988;128(3):515-23.
6. Menkes M., Comstock G.W., Vuilleumier J.P., et al. Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. *N Engl J Med* 1986;315:1250-54.
7. Dorgan J.F., Sowell A., Swanson C.A., et al. Relationships of serum carotenoids, retinol, alpha-tocopherol and selenium with breast cancer risk: results from a prospective study in Columbia, Missouri (United States). *Cancer Causes Control* 1998;9:89-97.
8. Yoshizawa K., Willett W.C., Morris S.J., et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. *J Natl Cancer Inst* 1998;90:1219-24.
9. Huttunen J.K. Selenium and cardiovascular diseases-an update. *Biomed Environ Sci* 1997;10(2-3):220-6.

More. . .



10. Orndahl G., Grimby G., Brimby A., et al. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study. *J Intern Med* 1994;235:205-210.
11. Baum M.K., Shor-Posner G., Lai S et al. High risk of HIV-related mortality is associated with selenium deficiency. *J Acq Imm Def Syndromes Human Retrovirology* 1997; 15:370-74.
12. Dworkin B.M. Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS). *Chemico-Biol Interactions* 1994;91(2-3):181-6.
13. Schrauzer G.N., Sacher J. Selenium in the maintenance and therapy of HIV-infected patients. *Chemico-Biol Interactions* 1994;91(2-3):199-205.
14. Peretz A.M., Neve J.D., Famaey J.P. Selenium in rheumatic diseases. *Seminars in Arthritis Rheum* 1991;20(5):305-16.
15. Kiremidjian-Schumacher L., Roy M. Selenium and immune function. *Zeitschrift fur Ernahrungswissenschaft* 1998;37Suppl 1:50-6.
16. Harrison P.R., Lanfear J., We L., et al. Chemopreventive and growth inhibitory effects of selenium. *Biomed Environ Sci* 1997;10(2-3):235-45.
17. Neve J. Selenium as a risk factor for cardiovascular diseases. *J Cardiovasc Risk* 1996;3(1):42-7.
18. Hocman G. Chemoprevention of cancer: selenium. *Intern J Biochem* 1988;20(2):123-32.
19. Gasmi A., Garnier R., Galliot-Guilley M., et al. Acute selenium poisoning. *Veterinary Human Toxicology* 1997;39(5):304-8.
20. Clark L.C., Combs G.F. Jr., Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA* 1996;276(24):1957.

### ***Shark Cartilage***

1. Thompson G.A., Yim S. Shark Cartilage and bovine cartilage-use in cancer. *Drugdex Drug Consult*. 1996.
2. Mathews J. Media feeds frenzy over shark cartilage as cancer treatment (news). *J Nat Cancer Inst* 1993;85:1000-1002.
3. Passwater R.A. Shark cartilage and cancer revisited: a follow-up interview with I. William Lane, Ph.D. <http://www.healthy.net/library/articles/passwater/lan2.htm>.
4. Ashar B., Bargo E. Shark cartilage-induced hepatitis (letter). *Ann Intern Med* 1996;125:780-781.

### ***Vanadium***

1. PharmInfoNet. 1997 Diabetes Highlights. Highlights from the 1997 meeting of the American Diabetes Association. Could vanadyl sulfate help diabetic patients? Levittown, PA: PIA Limited and Vir Sci Corporation. Available online at <http://www.pharminfo.com/disease/diabetes/ADA97/ADA-7112.html>; 1997.
2. Boden G., Chen X., Ruiz J., van Rossum G.D.V., Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. *Metab* 1996;45:1130-5.
3. Cohen N., Halberstam M., Shlimovich P., Chang C.J., Shamooh H., Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. *J Clin Invest* 1995;95:2501-9.
4. Halberstam M., Cohen N., Shlimovich P., Rossetti L., Shamooh H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. *Diabetes* 1996;45:659-66.
5. Goldfine A.B., Simonson D.C., Folli F., Patti M.E., Kahn C.R. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. *J Clin Endocrinol Metab* 1995;80:3311-20.
6. Harland B.F., Harden-Williams B.A. Is vanadium of human nutritional importance yet? *J Am Diet Assoc* 1994;94:891-4.
7. Fawcett J.P., Farquhar S.J., Walker R.J., Thou T., Lowe G., Goulding A. The effect of oral vanadyl sulfate on body composition and performance in weight-training athletes. *Int J Sport Nutr* 1996;6:382-90.

*More. . .*

8. Fawcett J.P., Farquhar S.J., Thou T., Shand B.. Oral vanadyl sulphate does not affect blood cells, viscosity or biochemistry in humans. *Pharmacol Toxicol* 1997;80:202-6.
9. Verma S., Cam M.C., McNeill J.H. Nutritional factors that can favorably influence the glucose/insulin system: Vanadium. *J Am Coll Nutr* 1998;17:11-8.
10. Czajka-Narins D.M. Minerals. In: Mahan L.K., Escott-Stump S, eds. Krause's Food, nutrition, and diet therapy. 9th ed. Philadelphia, PA: W.B. Saunders Co.; 1996:123-66.
11. Cannon J. HCRC FAQ Sheet. Vanadyl sulfate. Georgia: Georgia Council Against Health Fraud, Inc. Available online at <http://www.hcrc.org/contrib/cannon/vanadyl.htm>; 1997.
12. Naylor G.J. Vanadium and affective disorders. *Biological Psych* 1983;18:103-12.
13. Hosokawa S., Yoshida O. Vanadium in chronic hemodialysis patients. *Int J Artif Organs* 1990;13:197-9.
14. Romero R.A. Aluminum, vanadium, and lead intoxication of uremic patients undergoing hemodialysis in Venezuela. *Transplant Proc* 1994;26:330-2.
15. Los Alamos National Lab. Vanadium. Los Alamos, NM: TI Specialties. Available online at <http://www.callamer.com/~ezecho/elements/vanadium.html>; August 1998.
16. National Institute of Diabetes and Digestive and Kidney Diseases. Vanadium salts in the clinical treatment of diabetes mellitus. Bethesda, MD: National Institutes of Health. Available online at <http://www.nih.gov/grants/guide/1992/92.11.20/vanadium-salts.htm>; November 1992.
17. Eriksson J.W., Lonroth P., Posner B.I., Shaver A., Wesslau C., Smith U.P.G. A stable peroxovanadium compound with insulin-like actions in human fat cells. *Diabetologia* 1996; 39:235-42.
18. Ramanadham S., Cros G.H., Mongold J.J., Serrano J.J., McNeill J.H. Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin. *Can J Physiol Pharmacol* 1990;68:486-91.
19. Cohen N., Halberstam M. Shlimovich P., Chang C.J., Shamoon H., Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. *J Clin Invest* 1995;95(6):2501-9.
20. Halberstam M., Cohen N., Shlimovich P., Tossetti L., Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. *Diabetes* 1996;45(5):659-66.
21. Boden G., Chen X., Ruiz J., van Rossum G.D., Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. *Metabolism* 1996;45:1130-5.

### ***Vitamin B-Complex***

1. APhA. Handbook of Nonprescription Drugs, 11th Ed. AphA.
2. Consumer reports on Health, Sept 1998:6.
3. Schoenen J., Jacquy J., Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. *Neurology* 1998;50:466-70.
4. Morrison H.I., et al. Serum Folate and Risk of Fatal Coronary Heart Disease. *JAMA* 1996;275(24):1893-1895.
5. Robinson K., Mayer E., Jacobsen D.W. Homocysteine and coronary artery disease. *Cleve Clin J Med* 1994;61:438-450.
6. Lashner B.A., et al. The Effect of Folic Acid Supplementation on the Risk for Cancer or Dysplasia in Ulcerative Colitis. *Gastroenterology* 1997;112:29-32.
7. Baron J.A., et al. Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. *J Nat Can Inst* 1998;90(1):57-62.
8. Jennings E. Folic Acid as a Cancer-Preventing Agent. *Med Hypo* 19959.
9. Ortega R.M., et al. Functional and Psychic deterioration in Elderly People May Be Aggravated by Folate Deficiency. *J Nut* 1996;126(8):1992-9.
10. Fava M., et al. Folate, B12, and Homocysteine in Major Depressive Disorder. *Am J Psychiatry* 1997;154:426-8.
11. Godfrey P.S.A., et al. Enhancement of Recovery from Psychiatric Illness by Methylfolate. *Lancet* 1990;336:392-95.
12. Carney M., Sheffield B.F. Associations of Subnormal Serum Folate and Vitamin B12 and Effects of Replacement Therapy. *J Nerv Ment Dis* 1970;150:404-12.

More . . .

13. Guaraldi, et al. An Open Trial of Methylenetetrahydrofolate (MTHF) in Elderly Depressed patients. *Ann Clin Psychiatry* 1993;5:101-6.
14. Copeland D.A., Stoudkides C.A. Pyridoxine in Carpal Tunnel Syndrome. *Ann Pharmacotherapy* 1994;28:1042-4
15. Schaumburg H., et al. Sensory neuropathy from Pyridoxine Abuse. *N Engl J Med* 1983;309:445-8.
16. Lacy C. Drug Information Handbook. 4th ed. APhA.
17. Institute of Medicine. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic acid, biotin and choline. Washington,DC;National Academy Press:1998.
18. Huntington. *Oncology* 1996;10(11):1727-36,1742-3,1743-4.

### **Vitamin C**

1. APhA. Handbook of Nonprescription Drugs, 11th Ed. APhA
2. Knekt P., et al. Antioxidant Vitamin Intake and Coronary Mortality in a Longitudinal Population Study. *Am J Epidemiol* 1994;139:1180-9
3. Losonczy K.G., Harris T.B., Havlik R.J. Vitamin E and Vitamin C Supplement Use and Risk of All-cause Coronary Heart Disease Mortality in Older Persons: The Established Populations for Epidemiologic Studies of the Elderly. *Am J Clin Nutr* 1996;64:199-206.
4. Riemersma R.A., et al. Risk of Angina Pectoris and Plasma Concentrations of Vitamins A,C and E and Carotene. *Lancet* 1991;337:1-5.
5. Byers T., Gerrero N. Epidemiologic Evidence for Vitamin C and Vitamin E in Cancer Prevention. *Am J Clin Nutr* 1995;62(suppl):1385S-92S.
6. Kaegi E. Unconventional Therapies for Cancer: Vitamins A,C and E. *CMAJ* 1998;158(11):1483-8.
7. Niki E., et al. Interaction Among Vitamin C, Vitamin E, and B-carotene. *Am J Clin Nutr* 1995;62 (suppl):1322S-6S.
8. Sies H., Stahl W. Vitamins E and C, B-Carotene, and Other Carotenoids as Antioxidants. *Am J Clin Nutr* 1995;62(suppl):1315S-21S.
9. Hathcock J. Vitamin and Minerals: Efficacy and Safety. *Am J Clin Nutr* 1997;66:427-37.
10. Diplock A.T. Safety of Antioxidant Vitamins and B-carotene. *Am J Clin Nutr* 1995;62(suppl):1510S-6S.
11. Lacy C. Drug Information Handbook. 4th ed. APhA.
12. Blanchard J., Tozer T.N., Rowland M. Pharmacokinetic Perspectives on Megadoses of Ascorbic Acid. *Am J Clin Nutr* 1997;66:1165-71.
13. Levine M., et al. Determination of Optimal Vitamin C Requirements in Humans. *Am J Clin Nutr* 1995;62(suppl):1347S-56S.
14. Carr T., et al. Vitamins and Minerals, A Harvard Health Letter Special Report. Boston: Harvard Medical School Health Publications Group, 1995.

### **Vitamin E**

1. Sano M., Ernesto C., Thomas R. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease. *N Engl J Med* 1997; 336(17): 1216-1222.
2. Kushi L.H., Folsom A.R., Prineas R.J., et al., Dietary Antioxidant Vitamins and Death from Coronary Heart Disease in Postmenopausal Women. *N Engl J Med* 1996; 334(18): 1156-1190.
3. Rimm E.B., Stamfer M.J., Ascherio A., et al., Vitamin E Consumption and the Risk of Coronary Heart Disease in Men. *N Engl J Med* 1993; 1450-6.
4. Stampfer M.J., Hennekens C.H., Manson J.E., et al. Vitamin E Consumption and the Risk of Coronary Disease in Women. *N Engl J Med* 1993;328:1444-9.
5. Slattery M.L. Jacobs D.R., Dyer A., et al. Dietary Antioxidants and Plasma Lipids: The Cardia Study. *J Am Coll Nutrition* 1995; 14(6): 635-642.
6. Mosca L., Rubenfire M. Rock M.C., et al. Antioxidant Nutrient Supplementation Reduces the Susceptibility of Low Density Lipoprotein to Oxidation in Patients with Coronary Artery Disease. *J Am Coll Cardio*1997; 30(2): 392-9.
7. Freedman J.E., Farhat J.H., Loscalzo J., Keaney J.F. Alpha Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism. *Circulation* 1996;94(10): 2434-2440.

More. . .

8. Williams J.C., Forster L.A., Tull S.P., et al. Dietary Vitamin E Supplementation Inhibited Thrombin-induced Platelet Aggregation, but not Monocyte Adhesiveness, in Patients with Hypercholesterolaemia. *Intl J Exper Path* 1997; 259-266.
9. Rota S., McWilliam N.A., Baglin T.P., Byrne C.D. Atherogenic Lipoproteins Support Assembly of the Prothrombinase Complex and Thrombin Generation: Modulation by Oxidation and Vitamin E. *Blood* 1998; 91(2):508-515.
10. Stephens N.G., Parsons A., Scofield P.M., et al. Randomized Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 1996; 347:781-786.
11. Munro L.H., Burton G., Kelly F.J. Plasma RRR-alpha-tocopherol Concentrations are Lower in Smokers Than in Non-smokers after Ingestion of a Similar Oral Load of This Antioxidant Vitamin. *Clin Sci* 1997; 92:87-93.
12. Brown K., Morrice P.C., Duthie G.G. Erythrocyte Vitamin E and Plasma Ascorbate Concentrations in Relation to Erythrocyte Peroxidation in Smokers and Nonsmokers: Dose Response to Vitamin E Supplementation. *Am J Clin Nutr* 1997; 496-502.
13. Brown K.M., Morrice P.C., Duthie G.G. Erythrocyte Membrane Fatty Acid Composition of Smokers and Non-smokers: Effects of Vitamin E Supplementation. *Euro J Clin Nutr* 1998; 52:145-150.
14. Virtamo J., Rapola J.M., Ripatti S., et al. Effect of Vitamin E and Beta Carotene on the Incidence of Primary Nonfatal Myocardial Infarction and Fatal Coronary Heart Disease. *Arch Intern Med* 1998; 158:668-673.
15. Rapola J.M., Virtamo H., Haukka J.K., et al. Effect of Vitamin E and Beta Carotene on the Incidence of Angina Pectoris. *JAMA* 1996; 275(9):693-698.
16. Meydani S.N. Meydani M., Blumberg J.B. et al. Vitamin E Supplementation and In Vivo Immune Response in Healthy Elderly Subjects. *JAMA* 1997; 277(17): 1380-1386.
17. Fuchs J., Packer L. Vitamin E in Dermatological Therapy. Packer L., Fuchs J., eds. *Vitamin E in Health and Disease*. New York: *Macerl Dekker, Inc.*; 1992, 739-764.
18. Sakagami H. Sato H. K, Makino Y., et al. Effect of Alpha-Tocopherol on Cytotoxicity Induced by UV Irradiation and AntiOxidants. *Can Res* 1997; 17:2079-2082.
19. Havlik R.J., and the Plastic Surgery Educational Foundation DATA Committee. Vitamin E and Wound Healing. *Plas Recon Surg* 1997; 1901-1902.
20. deRijk MC, Breteler MM, denBreeijen JH, et al., Dietary Antioxidants and Parkinson Disease. The Rotterdam Study. *Arch Neur* 1997; 54(6):762-5.
21. Anonymous. Impact of Deprenyl and Tocopherol Treatment on Parkinson's Disease in DATATOP Patients Requiring Levodopa. Parkinson Study Group. *Ann Neur* 1996; 39(1):37-45.
22. Anonymous. Mortality in DATATOP: a Multicenter Trial in Early Parkinson's Disease. Parkinson Study Group. *Ann Neur* 1998; 43(3):318-25.
23. Lohr J.B., Caligiuri M.P. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. *J Clin Psych* 1996;57:167-173.
24. Heinonen O.P, Albane D., Virtamo J., et al. Prostate Cancer and Supplementation with Alpha-tocopherol and Beta-carotene: Incidence and Mortality in a Controlled Trial. *J Nat Can Inst* 1998; 90(6):414-5.
25. The Alpha Tocopherol, Beta Carotene Prevention Study Group. The Effect of Vitamin E and Beta-Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers. *N Eng J Med* 1994; 330:1029-35.
26. Verhoeven D.T, Assen N. Goldbohm R.A., et al. Vitamins C and E, Retinol, Beta-Carotene and Dietary Fiber in Relation to Breast Cancer Risk: A Prospective Cohort Study. *Br J Can* 1997; 75(1): 149-155.
27. Mezzetti M., LaVecchia C., Decarli A., et al. Population Attributable Risk for Breast Cancer: Diet, Nutrition, and Physical Exercise. *J Nat Can Inst* 1998; 90(5):389-94.
28. Varis K., Taylor P.R., Sipponen P., et al. Gastric Cancer and Premalignant Lesions in Atrophic Gastritis; a Controlled Trial on the Effect of Supplementation with Alpha-tocopherol and Beta-carotene. The Helsinki Gastritis Study Group. *Scan J Gastroen* 1998; 33(3):294-300.
29. Paolisso G., D'Amore A., Galzerano D., et al. Daily Vitamin E Supplements Improve Metabolic Control but not Insulin Secretion in Elderly Type II Diabetic Patients. *Diabetes Care* 1993; 16(11):1433-1437.

More. . .

30. Polisso G., D'Amore A., Giugliano D., et al. Pharmacologic Doses of Vitamin E Improve Insulin Action in Healthy Subjects and Non-insulin-dependent Diabetic Patients. *Am J Clin Nutr* 1993; 57(5):650-656.
31. Sanchez-Lugo L., Mayer-Davis E.J., Howard G., et al. Insulin Sensitivity and Intake of Vitamins E and C in African American, Hispanic, and non-Hispanic White Men and Women: the Insulin Resistance and Atherosclerosis Study. *Am J Clin Nutr* 1997; 66:1224-31.
32. Fuller C.J., Chandalia M., Garg A., et al. RRR-alpha-tocopheryl Acetate Supplementation at Pharmacologic Doses Decreases Low-density-lipoprotein Oxidative Susceptibility But Not Protein Glycation in Patients With Diabetes Mellitus. *Am J Clin Nutr* 1996; 63(5):753-759.
33. Jain S.K., McVie R., Jaramillo J.J., et al. Effect of Modest Vitamin E Supplementation on Blood Glycated Hemoglobin and Triglyceride Levels and Red Cell Indices in Type I Diabetic Patients. *Journal of the Am Coll of Nutr* 1996; 15(5):458-461.
34. Pozzilli P., Visalli N., Cavallo M.G., et al. Vitamin E and Nicotinamide Have Similar Effects in Maintaining Residual Beta Cell Function in Recent Onset Insulin-Dependent Diabetes (the IMDIAB IV study). *Eur J Endocrin* 1997; 137(5):234-9.
35. Geva E., Lessing J.B., Bartoov B., et al., The Effect of Antioxidant Treatment on Human Spermatozoa and Fertilization Rate in an In Vitro Fertilization Program. *Fertility and Sterility* 1996; 66(3):430-434.
36. Raju T.N., Langenberg P., Bhutani V., Quinn G.E. Vitamin E Prophylaxis to Reduce Retinopathy of Prematurity: A Reappraisal of Published Trials. *J Pediatrics* 131(6): 844-850.
37. Leske M.C., Chylack L.T., He Q., et al. Antioxidant Vitamins and Nuclear Opacities. *Ophthalmol* 1998; 105(5): 831-836.
38. Leske M.C., Wu S.Y., Sperduto R., et al. Biochemical Factors in the Lens Opacities Case-Control Study. *Arch Ophthalmol* 1995; 113:1113-1119.
39. Robertson J.M. Donner A.P., Trevithick J.R. Vitamin E Intake and Risk of Cataracts in Humans, *Annals NY Aca of Sci*; 1989: 372-382.
40. Leske M.C., Chylack L.T., Wu S.Y. The Lens Opacities Case-Control Study. *Arch Ophthalmol* 1991; 109: 244-251.
41. Mares-Perlman J.A., Klein B.E., Klein R., Ritter L.L. Relationship between Lens Opacities and Vitamin and Mineral Supplement Use. *Ophthalmol* 1994; 101(2): 315-324.
42. Teikari J.M. Laatikainen L., Rapola J.M., et al., Retinal Vascular Changes Following Supplementation With Alpha-Tocopherol or Beta-Carotene. *Acta Ophthalmologica Scandinavica* 1998; 76(1):68-73.
43. Teikari J.M. Virtamo J., Rautalahti M., et al. Long-term Supplementation with Alpha-tocopherol and Beta-carotene and Age Related Cataract. *Acta Ophthalmologica Scandinavica* 1997; 75(6):634-40.
44. Teikari J.M. Laatikainen L., Virtamo J., et al. *Acta Ophthalmologica Scandinavica* 1998; 76(2):224-9.
45. Edmonds S.E., Winyard P.G., Guo R., et al. Putative Analgesic Activity of Repeated Oral Doses of Vitamin E in the Treatment of Rheumatoid Arthritis. Results of a Prospective Placebo Controlled Double Blind Trial. *Ann Rheum Dis* 1997; 56:649-655.
46. AHFS Drug Information, 1998; 3025.
47. Tanyel M.C. Mancano L.D. Neurologic Findings in Vitamin E Deficiency. *Am Fam Phys* 1997; 55(1): 197-201.
48. Zimmer G., Thurich T., Scheer B. Membrane Fluidity and Vitamin E. In: Vitamin E in Health and Disease. New York: *Macerl Dekker, Inc.*; 1992, 207.
49. Bendich A., Machlin L.J. Safety of Oral Intake of Vitamin E. *Am J Clin Nutr* 1988; 48:612-9.
50. Bazzano C., DeAngeles S., Kleist G., Macedo N. Allergic Contact Dermatitis from Topical Vitamins A and E. *Contact Dermatitis* 1996; 35:261.
51. Harris B.D., Taylor J.S. Contact Allergy to Vitamin E Capsules: False-Negative Patch Tests to Vitamin E. *Contact Dermatitis* 1997;36:273.
52. Parsad D., Saini R., Verma N. Xanthamatus Reaction Following Contact Dermatitis From Vitamin E. *Contact Dermatitis* 1997; 37:294-311.

More . . .

53. Churukian M.M., Zemplyeni J., Steiner M., Kamer F.M., Cohen A. Post-rhinoplasty Epistaxis. *Arch Otolaryngol Head Neck Surg* 1988; 114:748-750.
54. Kim J., White R.H. Effect of Vitamin E on the Anticoagulant Response to Warfarin. *Am J Cardio* 1996; 77:545-546.
55. Corrigan J.J., et al. *Am J Clin Nutr* 1981; 34:1701.
56. Watanabe H., Kakihana M., Ohtsuka S., Sugishita Y. Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Vitamin E on Attenuation of the Development of Nitrate Tolerance. *Circulation* 1997; 96(8): 2545-2550.
57. The Royal Pharmaceutical Society. Martindale, *The Extra Pharmacopoeia*, 31st ed.
58. Vitamin and Mineral Safety. Council for Responsible Nutrition.

## Zinc

1. Godfrey J.C., et al. Zinc gluconate and the common cold: A controlled clinical study. *J Int Med Res* 20:234-246, 1992.
2. Mossad S.B., et al. Zinc gluconate lozenges for treating the common cold: A randomized, double-blind, placebo-controlled study. *Ann Intern Med* 125:81-88, 1996.
3. Smith D.S., et al. Failure of zinc gluconate in treatment of acute upper respiratory tract infections. *Antimicrob Agents Chemother* 33:646-648, 1989.
4. Weisman K., et al. Zinc gluconate lozenges for common cold: A double-blind clinical trial. *Dan Med Bull* 37:279-281, 1990.
5. Mackni M.L., et al. Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial. *JAMA* 279:1962-7, 1998.
6. Garland M.L., Hagemeyer K.O. The role of zinc lozenges in treatment of the common cold. *Ann Pharmacother* 32:63-9, 1998.
7. Marshall S. Zinc gluconate and the common cold. Review of randomized controlled trials. *Can Fam Physician* 44:1037-42, 1998.
8. Jackson J.L., et al. A meta-analysis of zinc salts lozenges and the common cold. *Arch Intern Med* 157:2373-6, 1997.
9. Eby G.A. Zinc ion availability—the determinant of efficacy in zinc lozenge treatment of common colds. *J Antimicrob Chemother* 40:483-93, 1997.
10. Geist F.C., et al. In vitro activity of zinc salts against human rhinoviruses. *Antimicrob Agents Chemother* 31:622-624, 1987.
11. Farr B.M., et al. Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. *Antimicrob Agents Chemother* 31:1183-1187, 1987.
12. Godfrey J.C., et al. Zinc for treating the common cold: review of all clinical trials since 1984. *Altern Ther Health Med* 2:63-72, 1996.
13. Novick S.G., et al. Zinc-induced suppression of inflammation in the respiratory tract, caused by infection with human rhinovirus and other irritants. *Med Hypotheses* 49:347-57, 1997.
14. Pihel K. et al. Exocytotic release from individual granules exhibits similar properties at mast and *Biophys J* 71:1633-40, 1996.
15. Shankar A.H., Prasad A.S. Zinc and immune function: the biological basis of altered resistance to infection. *Am J Clin Nutr*, 68(2 Suppl):447S-463S, 1998.
16. Freeland-Graves J.H., et al. Effect of Zinc Supplementation on Plasma High Density Lipoprotein and Zinc. *Am J Clin Nutr* 1982;35:988-992.
17. Fischer P.W.F., et al. Effect of Zinc Supplementation on Copper Status in Adult Man. *Am J Clin Nutr* 1984;40:743-746.
18. Yadrick M.D., et al. Iron, Copper and Zinc States: Response to Supplementation with Zinc or Zinc and Iron in Adult Females. *Am J Clin Nutr* 1989;49:145-150.
19. Chandra R.K. Excessive Intake of Zinc Impairs Immune Responses. *JAMA* 1984;252:1443-1446.

More . . .

- 
- ▲ *Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document.*

**PHARMACIST'S** <sup>®</sup>  
*LETTER*

**PRESCRIBER'S** <sup>®</sup>  
*LETTER*

*The most practical knowledge in the least time...*

2453 Grand Canal Blvd., Suite A, P.O. Box 8190, Stockton, CA 95208  
TEL (209) 472-2240 ❖ FAX (209) 472-2249

© 1998 Copyright by Therapeutic Research Center

Subscribers to Pharmacists Letter and Prescribers Letter can get detailed documents, like this one, on any topic covered in any issue by going to [www.pharmacistsletter.com](http://www.pharmacistsletter.com) or [www.prescribersletter.com](http://www.prescribersletter.com)